
Connecticut’s Medicaid program received $388,145 this month as part of a broader $56.5 million settlement that states and the federal government reached with Shire Pharmaceuticals.
The settlement resolves allegations that Philadelphia-based Shire “inappropriately” marketed several drugs for uses that have not been approved by the U.S. Food and Drug Administration. Terms of the agreement recently were announced by state Attorney General George Jepsen, Chief State’s Attorney Kevin Kane and state Department of Social Services Commissioner Roderick Bremby.
Connecticut and other states allege that Shire made claims about the drugs without sufficient clinical data to support them and without the backing of the FDA, according to state officials. The drugs involved are Adderall XR, Vyvanse, Daytrona, Lialda and Pentasa, and the misleading marketing took place between February 2007 and September 2010.
According to allegations brought forth by the states, Shire advertised Adderall XR as being better than other drugs at treating attention deficit hyperactivity disorder (ADHD) and also marketed it as a treatment for conduct disorder, which is a behavioral and emotional disorder most common in children and teenagers.
The company also claimed Vyvanse prevents certain negative consequences of ADHD and that it, along with Daytrona, is more difficult to abuse than Adderall XR or other ADHD medications, according to the states.
Shire also allegedly marketed Lialda to prevent colorectal cancer and Pentasa to treat indeterminate colitis and Crohn’s Disease, according to the states, when those indications were not supported by the FDA.
Adderall XR, Vyvanse and Daytrona are approved by the FDA to treat ADHD; Lialda and Pentasa are approved to treat mild to moderate ulcerative colitis, according to Jepsen.
The states claimed that Shire’s actions led to fraudulent claims filed with their Medicaid systems.
Under the terms of the settlement, Shire agreed to pay states and the federal government a total of $56.5 million. The bulk of that, $48.1 million, will go to Medicaid programs to resolve allegations that false claims were submitted to government health care programs as a result of Shire’s actions.
“Improper marketing of drugs leads to false and fraudulent claims against our Medicaid program,” Jepsen said in a statement. “We take all allegations of fraud and abuse very seriously and we will continue to work to hold accountable those who seek to defraud our taxpayers.”
In addition to the $388,145 for Connecticut’s Medicaid program, the state also got another $15,152 for certain drug programs administered by the state Department of Social Services.
The state has already received the money from the settlement, according to Jepsen’s office.
Shire officials said in a statement that the company cooperated with the government throughout the settlement process.
“We are pleased to have reached a resolution and to put this matter behind us,” Flemming Ornskov, the company’s chief executive officer, said in the statement. “The company has had, and will continue to have, a comprehensive compliance program and internal controls to ensure we comply with applicable laws and regulations.”
Support authentic, locally owned and operated public service journalism!
Under the settlement, Shire also entered into a Corporate Integrity Agreement with the U.S. Department of Health and Human Services. The department will monitor the company’s marketing and sales practices going forward.
In Connecticut, the Medical Fraud Control Unit of the Office of the Chief State’s Attorney, the Attorney General and DSS continually work to recover public resources and “protect the integrity of the Medicaid program,” Kane said.
More Health Care News & Analysis

6 Common Barriers Men Face When Seeking Mental Health Support
The outward effects of mental illness can often be dismissed as a sign of weakness or personal failure. For men, this type of social stereotyping can be especially hard to escape — being told to “man up” is a common refrain that can be reductive and stigmatizing.
Keep readingMedical Examining Board Fines Doctor $10,000
The state Medical Examining Board on Tuesday fined an Oxford doctor $10,000 for fraudulently using another doctor’s name and Drug Enforcement Agency registration number to prescribe controlled substances to a family member.
Keep reading
Clinical Trials With Immunotherapy Drugs Are Source Of Hope And Challenges In Treating Aggressive Breast Cancer
Joshalyn Mills of Branford and Nancy Witz of Kensington had the best possible results after being treated in clinical trials with immunotherapy drugs for aggressive breast cancer: Their tumors were eliminated. But while there are dramatic successes with immunotherapy drugs, there are also many failures, and researchers are trying to find out why in hopes…
Keep reading
Coalition of Health Insurers Questions Viability of Connecticut Partnership Plan
Members of Connecticut’s Health Care Future, a coalition of health insurers, hospitals, and businesses, are questioning whether Connecticut lawmakers have done enough this year to protect teachers and municipal employees from increases in health insurance premiums. “Despite repeated bailouts from taxpayers, the Connecticut Partnership Plan continues to be a fiscal Titanic that demonstrates why government-controlled health…
Keep reading
AG’s Tackle Mental Health Parity
Attorneys General in Connecticut and Rhode Island threw their support Monday behind a coalition of mental health advocacy groups asking a federal appeals court to revisit a recent ruling giving insurance companies more flexibility to deny mental health claims.
Keep reading
Budget Green Lights Psychedelic Therapies
Buried in the budget Gov. Ned Lamont signed this week is a provision that would create a pilot program to allow Connecticut to be the first-in-the-nation to study the impact of psychedelic drugs like psilocybin and MDMA on patients with depression and PTSD. The budget now creates a pilot program within the Department of Mental…
Keep reading